ADMA - ADMA Biologics GAAP EPS of -$0.07 revenue of $33.9M

• ADMA Biologics press release ( NASDAQ: ADMA ): Q2 GAAP EPS of -$0.07.
• Revenue of $33.9M (+90.4% Y/Y).
• Shares +2.8% .
• 2022 Financial Guidance: Enabled by the strong start to the year, ADMA anticipates total 2022 revenues will exceed $130 million. ADMA reiterates expectations for continued gross profit expansion and narrowing net losses as 2022 progresses.
• 2024-2025 Financial Guidance: The Company continues to anticipate generating approximately $250 million or more in topline revenue in 2024, and approximately $300 million or more thereafter. At these revenue levels, and based upon current assumptions, ADMA continues to forecast achieving corporate gross margins in the range of 40-50% and net income margins in the range of 20-30%. These assumptions translate to potential annual gross profit and net income in the range of $100-150 million and $50-100 million, respectively, during the 2024-2025 time period and beyond.

For further details see: